DE602004026903D1 - P-glycoprotein-inhibitor, verfahren zu dessen hersiesen enthält - Google Patents
P-glycoprotein-inhibitor, verfahren zu dessen hersiesen enthältInfo
- Publication number
- DE602004026903D1 DE602004026903D1 DE602004026903T DE602004026903T DE602004026903D1 DE 602004026903 D1 DE602004026903 D1 DE 602004026903D1 DE 602004026903 T DE602004026903 T DE 602004026903T DE 602004026903 T DE602004026903 T DE 602004026903T DE 602004026903 D1 DE602004026903 D1 DE 602004026903D1
- Authority
- DE
- Germany
- Prior art keywords
- hersesis
- glycoprotein inhibitor
- anticancer agent
- glycoprotein
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
- C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
- C04B35/632—Organic additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Ceramic Engineering (AREA)
- Health & Medical Sciences (AREA)
- Manufacturing & Machinery (AREA)
- General Health & Medical Sciences (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Structural Engineering (AREA)
- Materials Engineering (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- External Artificial Organs (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020030069582A KR100557093B1 (ko) | 2003-10-07 | 2003-10-07 | 다약제 내성 저해 활성을 갖는 테트라졸 유도체 및 그의제조방법 |
| PCT/KR2004/002550 WO2005033097A1 (en) | 2003-10-07 | 2004-10-06 | P-glycoprotein inhibitor, method for preparing the same and pharmaceutical composition comprising the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE602004026903D1 true DE602004026903D1 (de) | 2010-06-10 |
Family
ID=36500896
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE602004026903T Active DE602004026903D1 (de) | 2003-10-07 | 2004-10-06 | P-glycoprotein-inhibitor, verfahren zu dessen hersiesen enthält |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US7625926B2 (de) |
| EP (1) | EP1678162B1 (de) |
| JP (1) | JP4481992B2 (de) |
| KR (1) | KR100557093B1 (de) |
| CN (1) | CN1863795B (de) |
| AT (1) | ATE466008T1 (de) |
| AU (1) | AU2004277475B2 (de) |
| BR (1) | BRPI0415053B8 (de) |
| CA (1) | CA2541301C (de) |
| DE (1) | DE602004026903D1 (de) |
| DK (1) | DK1678162T3 (de) |
| ES (1) | ES2342290T3 (de) |
| HK (1) | HK1096399A1 (de) |
| IL (1) | IL174665A (de) |
| MX (1) | MXPA06003803A (de) |
| NO (1) | NO336127B1 (de) |
| NZ (1) | NZ546257A (de) |
| PL (1) | PL1678162T3 (de) |
| PT (1) | PT1678162E (de) |
| RU (1) | RU2317985C1 (de) |
| SI (1) | SI1678162T1 (de) |
| WO (1) | WO2005033097A1 (de) |
| ZA (1) | ZA200603538B (de) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0700773D0 (en) * | 2007-01-15 | 2007-02-21 | Portela & Ca Sa | Drug therapies |
| MX2009009304A (es) | 2007-03-01 | 2009-11-18 | Novartis Ag | Inhibidores de cinasa pim y metodos para su uso. |
| GB0706072D0 (en) * | 2007-03-28 | 2007-05-09 | Sterix Ltd | Compound |
| CN103333157A (zh) | 2008-09-02 | 2013-10-02 | 诺瓦提斯公司 | 作为激酶抑制剂的吡啶甲酰胺衍生物 |
| KR101466245B1 (ko) * | 2010-01-15 | 2014-12-01 | 한미사이언스 주식회사 | 테트라졸 메탄설폰산 염의 제조방법 및 이에 사용되는 신규 화합물 |
| TW201408641A (zh) | 2012-05-21 | 2014-03-01 | Novartis Ag | 可作爲激酶抑制劑之新穎環取代ｎ－吡啶基醯胺 |
| KR101986683B1 (ko) * | 2012-12-13 | 2019-06-10 | 한미약품 주식회사 | 테트라졸 유도체를 활성 성분으로 포함하는 용해도가 개선된 고체 분산체 |
| CN103804352B (zh) * | 2014-01-23 | 2017-06-13 | 中国药科大学 | 三氮唑苯乙基四氢异喹啉类化合物及其制备方法和应用 |
| KR20150135110A (ko) * | 2014-05-23 | 2015-12-02 | 한미정밀화학주식회사 | p-당단백질의 저해제 및 p-당단백질의 기질 약물을 포함하는 약제학적 조성물 |
| CN104327046B (zh) * | 2014-10-14 | 2017-11-17 | 中国药科大学 | 三氮唑‑n‑乙基四氢异喹啉类化合物及其制备方法和应用 |
| JO3737B1 (ar) * | 2015-07-21 | 2021-01-31 | Athenex Therapeutics Ltd | تركيبات علاجية من باكليتاكسيل تعطى عن طريق الفم ومثبط P-gp لعلاج السرطان |
| TWI715636B (zh) | 2015-09-30 | 2021-01-11 | 香港商慧源香港創新有限公司 | 口服紫杉烷組合物及方法 |
| CN112351779A (zh) * | 2018-04-13 | 2021-02-09 | 慧源医疗有限公司 | 用于治疗血管肉瘤的口服给药紫杉醇和P-gp抑制剂的治疗组合 |
| TW202038934A (zh) * | 2018-12-14 | 2020-11-01 | 香港商慧源香港創新有限公司 | 用於治療癌症之口服投予多西紫杉醇（ｄｏｃｅｔａｘｅｌ）和Ｐ－ｇｐ抑制劑的醫療組合 |
| US11752139B2 (en) * | 2018-12-14 | 2023-09-12 | Athenex HK Innovative Limited | Therapeutic combinations of orally administered irinotecan and a p-gp inhibitor for the treatment of cancer |
| US20220135548A1 (en) | 2019-02-14 | 2022-05-05 | Teva Pharmaceuticals International Gmbh | Solid state forms of n-[2-(2-{4-[2-(6,7-dimethoxy-3,4-dihydro-2(1h)-isoquinolinyl)ethyl]phenyl}-2h-tetrazol-5-yl)-4,5- dimethoxyphenyl]-4-oxo-4h-chromene-2-carboxamide and of its mesylate salt |
| WO2020230037A1 (en) * | 2019-05-13 | 2020-11-19 | Dr. Reddy's Laboratories Limited | Alternate process for the preparation of encequidar |
| WO2021044350A1 (en) * | 2019-09-04 | 2021-03-11 | Dr. Reddy’S Laboratories Limited | Solid forms of encequidar mesylate and processes thereof |
| EP4178679A1 (de) | 2020-07-10 | 2023-05-17 | Teva Czech Industries s.r.o. | Feste formen von n-[2-(2-{4-[2-(6,7-dimethoxy-3,4-dihydro-2(1h)-isochinolinyl)ethyl!phenyl}-2h-tetrazol-5-yl)4,5-dimethoxyphenyl)-4-oxo-4h-chromen-2-carboxamidmesylatsalz |
| JP2023544615A (ja) | 2020-10-07 | 2023-10-24 | アセネックス インコーポレイテッド | アセトアミド－フェニルテトラゾール誘導体およびその使用方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69111077T2 (de) * | 1990-11-06 | 1995-11-02 | Pfizer | Chinazolinderivate um die antitumorwirkung zu verbessern. |
| JP3223193B2 (ja) | 1991-08-09 | 2001-10-29 | 株式会社日清製粉グループ本社 | インドール誘導体およびそれらを有効成分とする抗癌剤耐性克服物質 |
| JP2718830B2 (ja) | 1992-07-10 | 1998-02-25 | ラボラトワール、グラクソ、ソシエテ、アノニム | アニリド誘導体 |
| GB9717576D0 (en) | 1997-08-19 | 1997-10-22 | Xenova Ltd | Pharmaceutical compounds |
| AU3408901A (en) * | 2000-02-15 | 2001-08-27 | Teijin Ltd | Cancer remedy comprising anthranilic acid derivative as active ingredient |
| CN100349888C (zh) | 2002-05-14 | 2007-11-21 | 埃克森诺瓦有限公司 | 药物化合物 |
| KR100580743B1 (ko) | 2003-10-08 | 2006-05-15 | 한미약품 주식회사 | 다약제 내성 저해 활성을 갖는 신규한 크로몬 유도체 또는이의 약제학적으로 허용가능한 염 및 이들의 제조 방법 |
-
2003
- 2003-10-07 KR KR1020030069582A patent/KR100557093B1/ko active IP Right Grant
-
2004
- 2004-10-06 EP EP04774778A patent/EP1678162B1/de active Active
- 2004-10-06 AU AU2004277475A patent/AU2004277475B2/en active Active
- 2004-10-06 PT PT04774778T patent/PT1678162E/pt unknown
- 2004-10-06 PL PL04774778T patent/PL1678162T3/pl unknown
- 2004-10-06 SI SI200431434T patent/SI1678162T1/sl unknown
- 2004-10-06 BR BRPI0415053A patent/BRPI0415053B8/pt active IP Right Grant
- 2004-10-06 DK DK04774778.7T patent/DK1678162T3/da active
- 2004-10-06 NZ NZ546257A patent/NZ546257A/en unknown
- 2004-10-06 AT AT04774778T patent/ATE466008T1/de active
- 2004-10-06 WO PCT/KR2004/002550 patent/WO2005033097A1/en active IP Right Grant
- 2004-10-06 JP JP2006532094A patent/JP4481992B2/ja active Active
- 2004-10-06 CA CA002541301A patent/CA2541301C/en active Active
- 2004-10-06 CN CN2004800293562A patent/CN1863795B/zh active Active
- 2004-10-06 US US10/574,098 patent/US7625926B2/en active Active
- 2004-10-06 DE DE602004026903T patent/DE602004026903D1/de active Active
- 2004-10-06 MX MXPA06003803A patent/MXPA06003803A/es active IP Right Grant
- 2004-10-06 ES ES04774778T patent/ES2342290T3/es active Active
- 2004-10-06 RU RU2006114427/04A patent/RU2317985C1/ru active
-
2006
- 2006-03-30 IL IL174665A patent/IL174665A/en active IP Right Grant
- 2006-05-04 ZA ZA200603538A patent/ZA200603538B/xx unknown
- 2006-05-05 NO NO20062019A patent/NO336127B1/no unknown
-
2007
- 2007-04-13 HK HK07103870.2A patent/HK1096399A1/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602004026903D1 (de) | P-glycoprotein-inhibitor, verfahren zu dessen hersiesen enthält | |
| TW200833370A (en) | Pharmaceutical composition containing low substituted hydroxypropylcellulose | |
| SE0400284D0 (sv) | Novel compounds | |
| MXPA05009985A (es) | Ligandos de receptores de canabinoides. | |
| WO2008016522A3 (en) | Hiv reverse transcriptase inhibitors | |
| TW200714583A (en) | Substituted gamma lactams as therapeutic agents | |
| ATE297203T1 (de) | Antithrombotische mitteln | |
| EP1679309A4 (de) | Antistress-arzneimittel und dessen medizinische verwendung | |
| ATE437872T1 (de) | Proteinkinaseinhibitoren | |
| EA200970585A1 (ru) | Бензамидные производные как агонисты ер-рецепторов | |
| TW200621737A (en) | 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof | |
| DE602005016297D1 (de) | Antithrombotische diamide | |
| EP1714961A4 (de) | Indazolverbindung und deren pharmazeutische verwendung | |
| UA97348C2 (en) | HETEROCYCLIC NF-kB INHIBITORS | |
| DE602005019316D1 (en) | Aromatische etherderivate als thrombin-hemmer | |
| UY29169A1 (es) | Derivados de 2-amido-4 feniltiazol, su preparacion y su aplicacion en terapeutica | |
| WO2008011117A3 (en) | Antiviral protease inhibitors | |
| TW200806291A (en) | Pharmaceutical formulations | |
| DK1750703T3 (da) | Fremgangsmåde til at reducere gastrointestinal toksitet forårsaget af indgivelsen af tegafur | |
| WO2004014868A8 (en) | Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors | |
| WO2004111008A3 (en) | Use of a compound of formula i for making a pharmaceutical composition | |
| DE60114640D1 (en) | Antithrombosemittel | |
| WO2007146856A3 (en) | Substituted gamma lactams as therapeutic agents | |
| GB0212410D0 (en) | Organic compounds | |
| MY139228A (en) | Imidazolinylmethyl aralkylsulfonamides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8327 | Change in the person/name/address of the patent owner |
Owner name: HANMI HOLDINGS CO., LTD., SEOUL, KR |
|
| 8364 | No opposition during term of opposition | ||
| R081 | Change of applicant/patentee |
Ref document number: 1678162 Country of ref document: EP Owner name: HANMI SCIENCE CO., LTD., KR Free format text: FORMER OWNER: HANMI HOLDINGS CO., LTD., SEOUL, KR Effective date: 20120906 |
|
| R082 | Change of representative |
Ref document number: 1678162 Country of ref document: EP Representative=s name: GRUENECKER, KINKELDEY, STOCKMAIR & SCHWANHAEUS, DE Effective date: 20120906 |